XLV250117C195000
- 0.05
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Stocks Rise On Core Inflation Slowdown, Banks Rally After Strong Q4 Earnings, Treasury Yields Plummet
Sector Update: Health Care Stocks Rise Premarket Wednesday
Intuitive Prelim. Q4 Results; Q4 Worldwide Da Vinci Procedures Grew Approximately 18% YoY, Da Vinci System Placements Totaled 493
Intuitive Sees Prelim. Q4 Revenue ~$2.41B Vs $2.204B Est.; FY24 Revenue $8.35B
UnitedHealth: The 'Number One Company On Sale' Ahead Of Q4 Earnings Report
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Investors Focus on Inflation, Earnings Reports
Zai Lab to Seek China Approval for Cervical Cancer Therapy After Positive Trial Data
Price Over Earnings Overview: Merck & Co
European Markets Gain, UK Inflation Slows to 2.5% in December
Microsoft, Applied Digital, Rigetti Computing, Eli Lilly, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Futu Morning Report | USA's December PPI unexpectedly cools down! Wall Street nervously prepares for CPI release day; quantum computing stocks rebound strongly, RGTI surges 48%.
In December, the USA's PPI unexpectedly cooled, growing by 0.2% month-on-month. The year-on-year growth of the December PPI and core PPI were 3.3% and 3.5% respectively, both the highest growth rates since February 2023; Biden has signed another executive order to accelerate the development of AI infrastructure.
The demand for weight loss drugs has dragged down Eli Lilly and Co's Q4 performance, which may be worse than expected, while the revenue guidance exceeds expectations, and the stock price once fell nearly 9%.
Eli Lilly and Co released a performance report showing that the Q4 revenue forecast fell short of expectations. The company explained that the growth in demand for weight loss drugs was lower than anticipated, and insufficient inventory levels at the end of the year affected performance. This marks the second consecutive quarter that the company has missed sales targets due to forecast discrepancies. Analysts state that the market has extremely high growth expectations for Eli Lilly and Co, leaving almost no room for error. Despite optimism that revenue will reach between 58 billion and 61 billion dollars in 2025, exceeding market expectations, the stock price fell nearly 9% in early trading on Tuesday.
Looking Into Johnson & Johnson's Recent Short Interest
ETF Earnings: Biggest Weeks for Major Funds as Holdings Report
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
The Momentum Factor ETF Is Coming off a Great 2024 but Still Oversold
Stocks Fail To Rise Despite Benign Producer Inflation, 30-Year Treasury Yields Hit 5%, Ely Lilly Tumbles: What's Driving Markets Tuesday?
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
10 Health Care Stocks With Whale Alerts In Today's Session
Eli Lilly and Co's revenue forecast for 2024 did not meet Analyst expectations, causing the stock price to plummet.
① Eli Lilly and Co expects global revenue of approximately 45 billion USD in 2024, an increase of 32%, but lower than the expected 45.5 billion USD; ② Eli Lilly and Co's global revenue for the fourth quarter of last year is expected to be 13.5 billion USD, an increase of 45%, but lower than the expected 14 billion USD.